Embera NeuroTherapeutics Overview

  • Year Founded
  • 2005

Year Founded

  • Status
  • Out of Business

  • Employees
  • 4

Employees

  • Latest Deal Type
  • Out of Business

Embera NeuroTherapeutics General Information

Description

Operator of a pharmaceutical company intended to develop novel treatments to potentially treat a range of addictions. The company's medication reduces the cravings and loss of control that drive addiction by targeting multiple pathways, to maximize potential efficacy more than either drug used alone, enabling patients to abstain from smoking and drug use.

Contact Information

Website
www.emberaneuro.com
Ownership Status
Out of Business
Financing Status
Formerly VC-backed
Corporate Office
  • 365 Boston Post Road
  • Suite 212
  • Sudbury, MA 01776
  • United States
+1 (978)
Primary Industry
Drug Discovery
Other Industries
Biotechnology
Vertical(s)
LOHAS & Wellness, Manufacturing, Life Sciences
Corporate Office
  • 365 Boston Post Road
  • Suite 212
  • Sudbury, MA 01776
  • United States
+1 (978)

Want detailed data on 11M+ companies?

What you see here scratches the surface

Request a free trial

Want to dig into this profile?

We’ll help you find what you need

Learn more

Embera NeuroTherapeutics Valuation & Funding

Deal Type Date Amount Raised to Date Post-Val Status Stage
13. Out of Business 12-Aug-2026 Completed Out of Business
12. Later Stage VC (Series A2) 11-Sep-2020 Completed Clinical Trials - Phase 2
11. Later Stage VC (Series B) 01-Aug-2020 Completed Clinical Trials - Phase 2
10. Later Stage VC (Series B) 09-Nov-2016 Completed Clinical Trials - Phase 1
9. Grant 01-Aug-2016 Completed Clinical Trials - Phase 1
8. Grant 26-Jul-2016 Completed Clinical Trials - Phase 1
7. Later Stage VC (Series A2) 29-Sep-2015 Completed Clinical Trials - Phase 1
6. Accelerator/Incubator 05-Aug-2015 Completed Clinical Trials - Phase 1
5. Grant 01-Jul-2014 $3.9M $9.5M Completed Clinical Trials - Phase 1
4. Later Stage VC (Series A2) 15-Aug-2011 $4.5M $9.5M Completed Startup
To view Embera NeuroTherapeutics’s complete valuation and funding history, request access »

Embera NeuroTherapeutics Cap Table

Stock # of Shares
Authorized		 Par Value Dividend Rate ($) Original
Issue Price		 Liquidation Liquidation
Pref. Multiple		 Conversion Price % Owned
Series B
Series A2
Series A1 1,357,100 $0.001000 $0.06 $1 $1 1x $1 3.74%
To view Embera NeuroTherapeutics’s complete cap table history, request access »

Embera NeuroTherapeutics Comparisons

Description
Primary
Industry
HQ Location
Employees
Total Raised
Post Valuation
Last
Financing
Details
Operator of a pharmaceutical company intended to develop novel treatments to potentially treat a range of addictions. Th
Drug Discovery
Sudbury, MA
4 As of 2024

Cambridge, MA
 

South San Francisco, CA
 
Add Comparison

PitchBook’s comparison feature gives you a side-by-side look at key metrics for similar companies. Personalize which data points you want to see and create visualizations instantly.

Request a free trial

Embera NeuroTherapeutics Competitors (2)

One of Embera NeuroTherapeutics’s 2 competitors is Spero Therapeutics, a Formerly VC-backed company based in Cambridge, MA.

Company Name Financing Status Location Employees Total Raised Last Financing Date/Type Last Financing Amount
Spero Therapeutics Formerly VC-backed Cambridge, MA
Achaogen Formerly VC-backed South San Francisco, CA
You’re viewing 2 of 2 competitors. Get the full list »

Embera NeuroTherapeutics Patents

  • 43

    Total Documents Applications and Grants

  • Total Patents Families

  • 9

    Granted

  • 3

    Pending

  • Expiring in next 12 mo

Embera NeuroTherapeutics Recent Patent Activity

Publication ID Patent Title Status First Filing Date Technology (CPC) Citations
US-20200360400-A1 Compositions and methods for the treatment of addiction, psychiatric disorders, and neurodegenerative disease Inactive 19-May-2017
WO-2018213713-A1 Compositions and methods for the treatment of addiction, psychiatric disorders, and neurodegenerative disease Inactive 19-May-2017
AU-2018230521-A1 Pharmaceutical compositions and uses thereof Active 10-Mar-2017
AU-2018230521-B2 Pharmaceutical compositions and uses thereof Inactive 10-Mar-2017
CA-3055940-A1 Pharmaceutical compositions and uses thereof Pending 10-Mar-2017 A61K9/1611
To view Embera NeuroTherapeutics’s complete patent history, request access »

Embera NeuroTherapeutics Signals

Growth Rate

Weekly
Growth
Weekly Growth

Size Multiple

Median
Size Multiple

Key Data Points

Similarweb Unique Visitors

Majestic Referring Domains

PitchBook’s non-financial metrics help you gauge a company’s traction and growth using web presence and social reach.

Request a free trial

Ready to get started?

Request a free trial

Embera NeuroTherapeutics FAQs

  • When was Embera NeuroTherapeutics founded?

    Embera NeuroTherapeutics was founded in 2005.

  • Where is Embera NeuroTherapeutics headquartered?

    Embera NeuroTherapeutics is headquartered in Sudbury, MA.

  • What is the size of Embera NeuroTherapeutics?

    Embera NeuroTherapeutics has 4 total employees.

  • What industry is Embera NeuroTherapeutics in?

    Embera NeuroTherapeutics’s primary industry is Drug Discovery.

  • Is Embera NeuroTherapeutics a private or public company?

    Embera NeuroTherapeutics is a Private company.

  • What is Embera NeuroTherapeutics’s current revenue?

    The current revenue for Embera NeuroTherapeutics is .

  • How much funding has Embera NeuroTherapeutics raised over time?

    Embera NeuroTherapeutics has raised $24.5M.

  • Who are Embera NeuroTherapeutics’s competitors?

    Spero Therapeutics and Achaogen are competitors of Embera NeuroTherapeutics.

Data Transparency

  • Meet our data hygiene team

    Discover how our experts ensure you’re getting the most accurate financial data in the industry.

    Read more

  • How PitchBook sources data

    Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.

    Discover our process